Israeli scientists have contributed to cancer research through foundational work on tumor suppressors and engineered immune cells. Moshe Oren and colleagues at the Weizmann Institute published early cloning research on mouse p53 in 1983. Zelig Eshhar’s group developed chimeric receptor approaches that gave T cells antibody-like target recognition. Today’s cancer medicines reflect additional work by many laboratories and clinical teams.
p53 research at Weizmann
In a 1983 paper, Moshe Oren, Alexander Levine, and colleagues reported cloning a cDNA specific for the murine p53 cellular tumor antigen. Oren’s laboratory publication record also lists a 1983 study by Oren, Bienz, Givol, Rechavi, and Zakut analyzing recombinant DNA clones specific for mouse p53. This chronology recognizes collaborative work rather than attributing the cloning to one scientist.
Researchers later established p53’s central role as a tumor suppressor across multiple laboratories. The initial cloning work was a building block for investigating the gene and protein, not itself a cancer treatment.
Engineered T cells and chimeric receptors
Eshhar and colleagues at Weizmann studied ways to redirect T cells toward selected targets by combining antibody-derived recognition with T-cell signaling components. The approach helped establish a foundation for chimeric antigen receptor (CAR) research. CAR T therapies later entered clinical practice for specific blood cancers after extensive work by research groups and companies internationally.
That history distinguishes a laboratory concept from an approved therapy. CAR T products are used for particular diagnoses and indications, with serious risks and eligibility requirements. They are not a general cancer cure. The Israeli contribution is specific: early work on redirected immune-cell recognition helped shape a field that others subsequently advanced into clinical products.
Explore Moshe Oren’s publication record, Weizmann’s account of Eshhar’s chimeric receptor research, and the Weizmann profile of Eshhar.